Nutraceuticals in rodent models as potential treatments for human Inflammatory Bowel Disease

Ghattamaneni, Naga K.R.; Panchal, Sunil K.; Brown, Lindsay

doi:10.1016/j.phrs.2018.04.015

Cited by 24 publications

(17 citation statements)

References 154 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IBS refers to several chronic inflammatory disorders of the gastrointestinal tract triggered by the action of environmental factors in genetically predisposed individuals [47]. The prevalence of IBS is highest in Europe followed by North America, although its incidence is also increasing in populations previously considered to be low risk, such as in Japan and India [48,49,50]. Although there is a low number of relevant clinical studies, the successful application of phytochemicals for IBS treatment seems to be promising [48].…”

Section: Discussionmentioning

confidence: 99%

Fermented Portulaca oleracea L. Juice: A Novel Functional Beverage with Potential Ameliorating Effects on the Intestinal Inflammation and Epithelial Injury

et al. 2019

View full text Add to dashboard Cite

P. oleracea L. contains high level of nutrients and biologically active compounds. Recently, lactic fermentation has been proposed as a biotechnological option to enrich the profile of biogenic compounds of Portulaca oleracea L. puree. This study investigated the capability of fermentation by selected lactic acid bacteria to enhance the restoring features of Portulaca oleracea juice towards intestinal inflammation and epithelial injury. Lactic acid fermentation markedly increased the total antioxidant capacity of P. oleracea juice, preserved the inherent levels of vitamins C, A, and E, and increased the bioavailability of the level of vitamin B2 and that of phenolics. The effects of fermented P. oleracea juice on a Caco-2 cell line were investigated using an in vitro model closest to the in vivo conditions. Fermented P. oleracea juice strongly decreased the levels of pro-inflammatory mediators and reactive oxygen species. It also counteracted the disruption of the Caco-2 cell monolayers treated with the inflammatory stimulus. We used a diversified spectrum of lactic acid bacteria species, and some effects appeared to be strains- or species-specific. Fermentation with Lactobacillus kunkeei B7 ensured the best combination for the content of bioactive compounds and the ability to counteract the intestinal inflammation and epithelial injury.

show abstract

Section: Discussionmentioning

confidence: 99%

Fermented Portulaca oleracea L. Juice: A Novel Functional Beverage with Potential Ameliorating Effects on the Intestinal Inflammation and Epithelial Injury

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Current therapies for IBD depend mainly on anti‐inflammatory drugs, antibiotics or biologics that are either not all effective, of high cost or with adverse effects. Therefore, the development of novel nutraceuticals or therapies for IBD remains imminently needed 4 …”

Section: Introductionmentioning

confidence: 99%

A novel danshensu derivative ameliorates experimental colitis by modulating NADPH oxidase 4‐dependent NLRP3 inflammasome activation

Pan

Ren

Liu

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

We have previously reported a novel compound [4‐(2‐acetoxy‐3‐((R)‐3‐(benzylthio)‐1‐methoxy‐1‐oxopropan‐2‐ylamino)‐3‐oxopropyl)‐1,2‐phenylene diacetate (DSC)], derived from danshensu, exhibits cytoprotective activities in vitro. Here, we investigated the effects and underlying mechanisms of DSC on dextran sodium sulphate (DSS)‐induced experimental colitis. We found that DSC treatment afforded significant protection against the development of colitis, evidencing by suppressed inflammatory responses and enhanced barrier integrity. Intriguingly, DSC specifically down‐regulated DSS‐induced colonic NADPH oxidase 4 (Nox4) expression, accompanied by a balanced redox status, suppressed nuclear factor‐κB (NF‐κB) and NLRP3 inflammasome activation and up‐regulated nuclear factor (erythroid‐derived 2)‐like 2 and haeme oxygenase‐1 expression. In vitro study also demonstrated DSC also markedly decreased Nox4 expression and activity associated with inhibiting reactive oxygen species generation, NF‐κB activation and NLRP3 inflammasome activation in bone marrow‐derived macrophages. Either lentiviral Nox4 shRNA‐mediated Nox4 knockdown or Nox4‐specific small‐interfering RNA mimicked effects of DSC by suppressing NLPR3 inflammasome activation to alleviate experimental colitis or inflammatory macrophage response. Collectively, our results provide the first evidence that DSC ameliorates experimental colitis partly through modulating Nox4‐mediated NLRP3 inflammasome activation.

show abstract

“…In particular, the use of animal models is necessary to develop new therapies, since the conventional treatments for IBD (e.g., corticosteroids and immunomodulators) and biological therapies have many side effects and relative responses [ 18 ]. In this sense, nutraceuticals, including bioactive compounds such as polyphenols from berries with anti-inflammatory and antioxidant activities, could be potential agents for the treatment of IBD in humans [ 19 ]. Amongst them, Aristotelia chilensis (Mol) Stuntz ( Elaeocarpaceae) , commonly known as maqui, is an edible black-colored fruit and endemic Chilean berry which has an exceptionally high content of phenolic compounds with high antioxidant capacity [ 20 ] and, less studied, anti-inflammatory effects [ 21 ].…”

Section: Introductionmentioning

confidence: 99%

Polyphenolic Maqui Extract as a Potential Nutraceutical to Treat TNBS-Induced Crohn’s Disease by the Regulation of Antioxidant and Anti-Inflammatory Pathways

et al. 2020

View full text Add to dashboard Cite

Nutraceuticals include a wide variety of bioactive compounds, such as polyphenols, which have been highlighted for their remarkable health benefits. Specially, maqui berries have shown great antioxidant activity and anti-inflammatory effects on some inflammatory diseases. The objectives of the present study were to explore the therapeutic effects of maqui berries on acute-phase inflammation in Crohn’s disease. Balb/c mice were exposed to 2,4,6-trinitrobenzene sulfonic acid (TNBS) via intracolonic administration. Polyphenolic maqui extract (Ach) was administered orally daily for 4 days after TNBS induction (Curative Group), and for 7 days prior to the TNBS induction until sacrifice (Preventive Group). Our results showed that both preventive and curative Ach administration inhibited body weight loss and colon shortening, and attenuated the macroscopic and microscopic damage signs, as well as significantly reducing transmural inflammation and boosting the recovery of the mucosal architecture and its muco-secretory function. Additionally, Ach promotes macrophage polarization to the M2 phenotype and was capable of down-regulating significantly the expression of inflammatory proteins COX-2 and iNOS, and at the same time it regulates the antioxidant Nrf-2/HO-1 pathway. In conclusion, this is the first study in which it is demonstrated that the properties of Ach as could be used as a preventive and curative treatment in Crohn’s disease.

show abstract

Nutraceuticals in rodent models as potential treatments for human Inflammatory Bowel Disease

Cited by 24 publications

References 154 publications

Fermented Portulaca oleracea L. Juice: A Novel Functional Beverage with Potential Ameliorating Effects on the Intestinal Inflammation and Epithelial Injury

Fermented Portulaca oleracea L. Juice: A Novel Functional Beverage with Potential Ameliorating Effects on the Intestinal Inflammation and Epithelial Injury

A novel danshensu derivative ameliorates experimental colitis by modulating NADPH oxidase 4‐dependent NLRP3 inflammasome activation

Polyphenolic Maqui Extract as a Potential Nutraceutical to Treat TNBS-Induced Crohn’s Disease by the Regulation of Antioxidant and Anti-Inflammatory Pathways

Contact Info

Product

Resources

About